Deucravacitinib

Excerpt

Deucravacitinib is a targeted treatment for patients with moderate-to-severe plaque psoriasis who qualify for systemic therapy or phototherapy. This medication selectively inhibits the tyrosine kinase 2 (Tyk2) protein, providing greater efficacy and a superior safety profile compared to other biological agents, particularly apremilast. Deucravacitinib may be administered orally once daily, which enhances patient compliance and improves treatment outcomes.